EUVIMEDEUVIMED entdecken
Crossref

Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes

Sohee Park, Han Eol Jeong, Sungho Bea, Oriana H Y Yu, Young Min Cho iD, Seng Chan You, Kenneth K C Man, Ju-Young Shin iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Sohee Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Ministry of Food and Drug Safety, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess the risk of amputation associated with sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) among patients with type 2 diabetes, across categories of baseline cardiovascular disease (CVD) and diuretic use (DU). Materials and Methods We conducted an active comparator, new‐user cohort study using Korea's nationwide claims data (2015‐2020). The study cohort consisted of patients with type 2 diabetes who initiated SGLT2is or dipeptidyl peptidase‐4 inhibitors (DPP4is). Cohort entry was defined by first prescription date. We then classified patients into four discrete subcohorts based on their baseline status of CVD and DU as (1) CVD+/DU+, (2) CVD+/DU‐, (3) CVD‐/DU+ and (4) CVD‐/DU‐. We performed 1:1 propensity score (PS) matching within each cohort and estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for the risk of amputation with SGLT2is versus DPP4is using Cox models.

Results

We identified 219 900 PS‐matched pairs of SGLT2is and DPP4is (CVD+/DU+, n = 11 719; CVD+/DU‐, n = 26 092; CVD‐/DU+, n = 26 894; and CVD‐/DU‐, n = 155 195), with well‐balanced baseline covariates across all cohorts. Significantly lower risks of amputation with SGLT2is versus DPP4is were found in CVD+/DU+ (HR 0.36, 95% CI 0.14‐0.90), CVD+/DU‐ (0.45, 0.21‐0.99) and CVD‐/DU‐ (0.48, 0.33‐0.70), but not in CVD‐/DU+ (0.54, 0.26‐1.12). Consistent trends in estimates were found across various sensitivity analyses.

Conclusions

Initiating SGLT2is against DPP4is did not increase the risk of amputation across patient populations of varying vulnerability. These findings based on routine practice will reassure clinicians of the safety of SGLT2is with regard to amputation risk in selected high‐risk patients with type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesDipeptidyl-Peptidase IV InhibitorsSymportersHumansCohort StudiesDiureticsRisk FactorsAmputation, SurgicalGlucoseSodiumHypoglycemic Agents

Stichwörter der Autor:innen

SGLT2 inhibitorsamputationcardiovascular diseasediureticstype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDiureticsDipeptidyl-Peptidase IV InhibitorsSymportersGlucoseSodiumHypoglycemic Agents

Autor:innen und Institutionen

  • School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
  • Research Department of Practice and Policy, UCL School of Pharmacy, London, UK.
  • Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Republic of Korea.
  • Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
  • Division of Endocrinology and Metabolism, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
  • Department of Internal Medicine Seoul National University College of Medicine, Seoul, South Korea.

ORCID-Profile: Young Min Cho, Ju-Young Shin

Förderung

  • Ministry of Food and Drug Safety
  • National Research Foundation of Korea

Zitieren

APA

Park, S., Jeong, H. E., Bea, S., Yu, O. H. Y., Cho, Y. M., You, S. C., Man, K. K. C., & Shin, J. Y. (2023). Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15221

Vancouver

Park S, Jeong HE, Bea S, Yu OHY, Cho YM, You SC, et al. Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15221

BibTeX
@article{Park2023,
  author = {Park, Sohee and Jeong, Han Eol and Bea, Sungho and Yu, Oriana H Y and Cho, Young Min and You, Seng Chan and Man, Kenneth K C and Shin, Ju-Young},
  title = {Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15221}
}
Kostenlos starten →